These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31686907)

  • 1. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vandetanib in the management of medullary thyroid cancer.
    Brassard M; Rondeau G
    Biologics; 2012; 6():59-66. PubMed ID: 22500115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
    Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating medullary thyroid cancer in the age of targeted therapy.
    Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
    Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on the Management of Medullary Thyroid Carcinoma.
    Kim BH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
    Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
    Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
    Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
    J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.
    Pozo K; Zahler S; Ishimatsu K; Carter AM; Telange R; Tan C; Wang S; Pfragner R; Fujimoto J; Grubbs EG; Takahashi M; Oltmann SC; Bibb JA
    Oncotarget; 2018 Dec; 9(102):37662-37675. PubMed ID: 30701022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.
    Deshpande H; Roman S; Thumar J; Sosa JA
    Clin Med Insights Oncol; 2011; 5():213-21. PubMed ID: 21836817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
    Giunti S; Antonelli A; Amorosi A; Santarpia L
    Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
    Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
    Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib for the treatment of metastatic medullary thyroid cancer.
    Degrauwe N; Sosa JA; Roman S; Deshpande HA
    Clin Med Insights Oncol; 2012; 6():243-52. PubMed ID: 22723734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.
    Sugawara M; Ly T; Hershman JM
    Horm Cancer; 2012 Dec; 3(5-6):218-26. PubMed ID: 23011723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative BRAF activating fusion in a medullary thyroid cancer.
    Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
    Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report.
    Ashraf S; Shah N; Saad M; Jyala A; Vittorio TJ
    Cureus; 2022 Apr; 14(4):e24556. PubMed ID: 35651469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.